Communication Events Insurance Coverage and Processing 
PharmaTech
JUNE 10, 2025
The decision was communicated through a Department of Health and Human Services (HHS) press release. It provides evidence-based recommendations on the use of vaccines for children and adults, informs decisions about insurance coverage, and helps determine eligibility for publicly funded programs such as Vaccines for Children (VFC).
Pharmaceutical Technology
JUNE 6, 2025
The approval process for cell and gene therapy candidates is tricky, however, given their high-cost and oft-debated benefit-risk ratio. RFK Jr did not question their importance, and acknowledged panellists’ calls for faster regulatory processes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 23, 2025
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. We may still continue to send you service-related and other non-promotional communications. In 2024, Otsuka announced the acquisition of US-based Jnana Therapeutics in a deal worth up to $1.1bn. Sign up for our daily news round-up!
Pharmaceutical Technology
JUNE 23, 2025
Better insights into how SDoH affects health can highlight the systemic influences that leave certain groups with worse health outcomes than others, despite similar health insurance coverage or access. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Putting Patients First Blog
JANUARY 10, 2024
Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.
Pharmaceutical Technology
NOVEMBER 30, 2022
In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Medicare Part A, Part B, and Part D do not generally cover approved weight loss medications like Saxenda, but Medicare Advantage plans may allow for expanded coverage, as per the Medicare.org site.
Pharmaceutical Technology
NOVEMBER 30, 2022
In the US, most private health insurers have been slow to cover the cost of anti-obesity therapeutics. Medicare Part A, Part B, and Part D do not generally cover approved weight loss medications like Saxenda, but Medicare Advantage plans may allow for expanded coverage, as per the Medicare.org site.
Expert insights. Personalized for you.
85 
Let's personalize your content